Following successful Phase II trials in patients with acute kidney injury associated with sepsis [17] and inflammatory bowel diseases [14], a multi-national Phase III trial of recombinant AP in 1400 patients with sepsis-associated-acute kidney injury has recently been initiated. Here, DHCR7-DT is linked to inflammatory bowel disease.